Ignite Creation Date:
2025-12-24 @ 9:48 PM
Ignite Modification Date:
2026-01-03 @ 3:04 PM
Study NCT ID:
NCT02547532
Status:
COMPLETED
Last Update Posted:
2018-08-01
First Post:
2015-09-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
Sponsor:
Fondazione Salvatore Maugeri
Organization:
Study Overview
Official Title:
Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AATD
Brief Summary:
In the context of the increasing evidence of the pathogenetic role of microbiome in COPD, our aim is to determine the total and specific bacterial and viral load in sputa from patients with COPD due to AATD and to correlate these findings with cellular, biochemical and immunological characteristics of sputa. These quantitative data obtained from sputum will be analyzed in the context of the clinical and physiological parameters of the patients.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: